Discover and read the best of Twitter Threads about #ACR19
Most recents (3)
#ACR22 epidemiology posters 
Abs 0700 @zach_wallace_md
💻Using NLP, ML algorithms to identify ANCA vasculitis cases
They also looked at the difference in performance metrics with/without filtering keywords
An explosion of NLP studies in rheum! #ACR22
💻Using NLP, ML algorithms to identify ANCA vasculitis cases
They also looked at the difference in performance metrics with/without filtering keywords
An explosion of NLP studies in rheum! #ACR22
@zach_wallace_md Abs 0732 Ho, et al. @JYazdanyMD @MilenaGianfran
💻Part of the explosion of NLP studies in rheum
Here the UCSF group aimed to capture VZV cases (differentiate from vaccination); and to capture active vs historical cases
See their diagrams explaining the steps!
#ACR22
💻Part of the explosion of NLP studies in rheum
Here the UCSF group aimed to capture VZV cases (differentiate from vaccination); and to capture active vs historical cases
See their diagrams explaining the steps!
#ACR22
Path in GPA vs RP
Relapsing polychondritis criteria #ACR19
Absence of typical manifestation of RP such as saddle nose deformity, ear inflammation, and subglottic stenosis does not exclude, but delays Dx #ACR19
SQ MTX offers the advantage of delivering 100% of the med to the patient.
Split dose oral MTX also increase bioavailability >28% over single dose.
Also important to make sure you escalate the dose of MTX up to 20-25mg/wk.
#ACR19
Split dose oral MTX also increase bioavailability >28% over single dose.
Also important to make sure you escalate the dose of MTX up to 20-25mg/wk.
#ACR19
2/3 of patients don’t achieve low disease activity or remission on MTX alone. These pts need another agent.
Keeping them on MTX increases the efficacy of some biologics (TNFi, RTX) and helps prevent drug-blocking antibodies.
#ACR19
Keeping them on MTX increases the efficacy of some biologics (TNFi, RTX) and helps prevent drug-blocking antibodies.
#ACR19
